Here are the 424B prospectus supplements from Freenome, Inc. (FRNM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow FRNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FRNM filings page.
Freenome, Inc. has registered 75,188,742 shares of common stock for resale by selling securityholders. Separately, Freenome announced the launch of SimpleScreen Lung and a combined screening option pairing it with SimpleScreen CRC through one blood draw, using two independently validated, indication-specific tests.
SimpleScreen Lung is a laboratory-developed test intended for adults ages 50 to 80 with a ≥20 pack-year smoking history who are not currently participating in guideline-recommended screening; it has not been reviewed or cleared/approved by the FDA. In an independent cohort of 172 lung cancer cases and 436 controls, it showed 85% sensitivity at 50% specificity and 99.8% negative predictive value. The FDA-approved SimpleScreen CRC test showed 81% sensitivity for CRC, 90% specificity for advanced colorectal neoplasia and 99.9% negative predictive value in PREEMPT CRC, which enrolled more than 48,000 participants.
Freenome, Inc. (FRNM) filed a resale shelf prospectus on Form S-1/424B3 covering up to 75,188,742 shares of common stock that may be offered from time to time by selling securityholders. The shares comprise PIPE shares, business-combination consideration shares, option and RSU shares, Roche note conversion shares and Private Warrant shares.
Freenome will not receive proceeds from sales by selling securityholders, but may receive up to approximately $36.3 million if options and the Private Warrant are exercised for cash, for general corporate purposes. The company focuses on blood-based multiomics cancer screening, with FDA-approved SimpleScreen CRC, and operates as an emerging growth and smaller reporting company with significant historical losses and substantial R&D, regulatory, competitive, financing, data-privacy, cybersecurity and AI-related risks described in detail in its risk factors.